Patents by Inventor Kunyuan Cui

Kunyuan Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220054443
    Abstract: Provided is a drug containing a liver targeting specific ligand and a thyroid hormone receptor agonist in its structure, which is a new drug structure formed by linking the liver targeting specific ligand with the thyroid hormone receptor agonist through a branched chain, a linker and a linking chain. Thyroid hormone receptors (TRs) are divided into two subtypes, TR-? and TR-?, wherein, TR-? is mainly expressed in liver, and TR-? is mainly expressed in heart, nervous system, etc. In certain embodiments, it is envisaged that the provided drug has the action of liver targeting, can specifically bring the thyroid hormone receptor agonist into liver, without entering heart and other issues, and may thereby avoid side effects caused by the action of the thyroid hormone receptor agonist on other issues, and maintain its therapeutic efficacy in the treatment of lipid metabolism disorders and related complications.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 24, 2022
    Applicant: KYLONOVA (XIAMEN) BIOPHARMA CO., LTD.
    Inventor: Kunyuan CUI
  • Patent number: 9777278
    Abstract: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: October 3, 2017
    Assignee: BIOMICS BIOTECHNOLOGIES CO., LTD
    Inventors: Dong Liang, David Sweedler, Kunyuan Cui
  • Publication number: 20160206749
    Abstract: Cholesterol moieties are linked to specific ends of double-stranded RNA, preferably a small, interfering (si)RNA or to a dsHybrid. The dsHybrid has one strand comprised of DNA and one strand comprised of RNA. Preferably the sense strand is the DNA strand and the antisense strand is the RNA strand of the dsHybrid. The present invention is based upon the discovery that a cholesterol moiety, if linked to a specific end or ends of the sense or antisense strands of a siRNA, can enhance the delivery and silencing efficiency of the siRNA directed against its target message, in comparison with a corresponding, non-conjugated siRNA. Conjugated siRNAs and dsHybrids of the invention are optionally formulated with, or coordinately administered with, a secondary delivery-enhancing agent, such as a delivery-enhancing peptide, to enhance intracellular delivery and uptake of the conjugated siRNAs or dsHybrid.
    Type: Application
    Filed: December 15, 2015
    Publication date: July 21, 2016
    Applicant: Marina Biotech, Inc.
    Inventors: Mohammad Ahmadian, Kunyuan Cui, Lishan Chen, Shu-Chih Chen Quay, Michael E. Houston, JR.
  • Publication number: 20160040170
    Abstract: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.
    Type: Application
    Filed: August 14, 2015
    Publication date: February 11, 2016
    Inventors: Dong Liang, David Sweedler, Kunyuan Cui
  • Patent number: 9233971
    Abstract: What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure: When substituents R and R? that are hydrophobic substituents, the macrocyclic compound functions as a lipid and is compatible with lipid systems, including liposomes and lipid particles. When present in certain lipid systems, the macrocyclic compound enhances the ability of the lipid system to facilitate delivery of therapeutic molecules to target cells in a mammalian subject.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: January 12, 2016
    Inventors: Kunyuan Cui, Dong Liang
  • Publication number: 20150252369
    Abstract: A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal.
    Type: Application
    Filed: December 10, 2014
    Publication date: September 10, 2015
    Applicant: MARINA BIOTECH, INC.
    Inventors: Mohammad Ahmadian, Kunyuan Cui, Lishan Chen, Shu-Chih Chen Quay, Michael E. Houston, JR.
  • Patent number: 9080186
    Abstract: This disclosure provides compositions consisting of solid mixture of cationic lipids and a polynucleotide, wherein the cationic lipid molecules form a water-insoluble ionic complex with the polynucleotide. What is also described is an anhydrous mixture of the cationic lipids and the polynucleotide solubilized in an organic or polar aprotic solvent. The anhydrous compositions are useful in preparing therapeutic formulations and in the diagnosis and treatment of diseases and conditions. The compositions are useful for delivery of agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Grant
    Filed: May 16, 2010
    Date of Patent: July 14, 2015
    Assignee: Agave Pharma, Incorporated
    Inventors: Kunyuan Cui, Dong Liang
  • Patent number: 8940857
    Abstract: A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: January 27, 2015
    Assignee: Marina Biotech, Inc.
    Inventors: Mohammad Ahmadian, Kunyuan Cui, Lishan Chen, Shu-Chih Chen, Michael E. Houston, Jr.
  • Publication number: 20130156851
    Abstract: What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure: When substituents R and R? that are hydrophobic substituents, the macrocyclic compound functions as a lipid and is compatible with lipid systems, including liposomes and lipid particles. When present in certain lipid systems, the macrocyclic compound enhances the ability of the lipid system to facilitate delivery of therapeutic molecules to target cells in a mammalian subject.
    Type: Application
    Filed: August 26, 2011
    Publication date: June 20, 2013
    Inventors: Kunyuan Cui, Dong Liang
  • Publication number: 20130072424
    Abstract: Compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double stranded ribonucleic acids (dsRNAs) and one or more peptides. The compounds, compositions and methods are useful for modulating gene expression by RNA interference.
    Type: Application
    Filed: May 18, 2012
    Publication date: March 21, 2013
    Applicant: MARINA BIOTECH, INC.
    Inventors: Roger C. Adami, Tianying Zhu, Kunyuan Cui, Michael E. Houston, JR., Lishan Chen, Yuching Chen
  • Publication number: 20120289584
    Abstract: This disclosure provides compositions that are useful combined with therapeutics, and in the diagnosis and treatment of diseases and conditions. The compositions are useful for delivery of agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Application
    Filed: May 16, 2010
    Publication date: November 15, 2012
    Applicant: AGAVE PHARMA, INCORPORATED
    Inventors: Kunyuan Cui, Dong Liang, David Sweedler
  • Patent number: 8299236
    Abstract: Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference (RNAi). The siNA/polypeptide compositions and methods of the invention provide effective tools to modulate gene expression and alter phenotype in mammalian cells, including by altering phenotype in a manner that eliminates disease symptoms or alters disease potential in targeted cells or subject individuals to which the siNA/polypeptide compositions are administered.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: October 30, 2012
    Assignee: Marina Biotech, Inc.
    Inventors: Lishan Chen, Kunyuan Cui, Yuching Chen, Sasha J. Mayer, Michael E. Houston, Jr.
  • Publication number: 20100316707
    Abstract: A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal.
    Type: Application
    Filed: August 30, 2010
    Publication date: December 16, 2010
    Applicant: MDRNA, INC.
    Inventors: Mohammad Ahmadian, Kunyuan Cui, Lishan Chen, Shu-Chih Chen, Michael E. Houston, JR.
  • Publication number: 20100247482
    Abstract: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a PN159 analog or conjugate.
    Type: Application
    Filed: April 23, 2008
    Publication date: September 30, 2010
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Kunyuan Cui, Shu-Chih Chen, Michael E. Houston, JR., Steven C. Quay
  • Publication number: 20100129460
    Abstract: Compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double stranded ribonucleic acids (dsKNAs) and one or more peptides. The compounds, compositions and methods are useful for modulating gene expression by RNA Interference.
    Type: Application
    Filed: October 13, 2006
    Publication date: May 27, 2010
    Applicant: Nastech Pharmaceutical Company Inc.
    Inventors: Roger C. Adami, Tianying Zhu, Kunyuan Cui, Michael E. Houston, JR., Lishan Chen, Yuching Chen
  • Publication number: 20100113332
    Abstract: What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting production of tumor necrosis factor-? (TNF-?) in the mammal.
    Type: Application
    Filed: September 27, 2005
    Publication date: May 6, 2010
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Lishan Chen, Kunyuan Cui, Michael E. Houston, JR., Yuching Chen
  • Patent number: 7696343
    Abstract: The use of antagonists to JAM-1 Claudin-4 and occludin to open tight junctions. The antagonists include, by way of example antibodies and antibody fragments that bind to the proteins and small interfering nucleic acids that downregulate the mRNA encoding the proteins.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: April 13, 2010
    Assignee: MDRNA, Inc.
    Inventors: Kunyuan Cui, Benjamin H Dutzar
  • Publication number: 20100022618
    Abstract: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.
    Type: Application
    Filed: September 5, 2008
    Publication date: January 28, 2010
    Inventors: Dong Liang, David Sweedler, Kunyuan Cui
  • Publication number: 20090274658
    Abstract: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a conjugate of a TJMP analogue, or complexes thereof. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject.
    Type: Application
    Filed: June 8, 2009
    Publication date: November 5, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY, INC.
    Inventors: Kunyuan Cui, Shu-Chih Chen Quay, Kristine T. Fry
  • Publication number: 20090220435
    Abstract: Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.
    Type: Application
    Filed: July 27, 2006
    Publication date: September 3, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Shu-Chih Chen Quay, Kunyuan Cui, Anthony P. Sileno, Paul Hickok Johnson, Michael E. Houston, Henry R. Costantino, Michael V. Templin